There are currently 385 clinical trials in Scottsdale, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Arizona, Mayo Cliinic - Scottsdale, Mayo Clinic and Mayo Clinic Arizona. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT04282044
Recruiting
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovaria... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Register for Updates
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
NCT05229588
Recruiting
The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Gastrointestinal Malignancies
Register for Updates
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT04197687
Recruiting
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Register for Updates
Vincere Biobank Research Protocol
NCT05954299
Recruiting
The Vincere Biobank aims to make quality biospecimens and associated clinical data available for research studies related to advancing medicine and improving care for patients, including cancer screening, treatment, and care.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: Vincere Cancer Center, Scottsdale, Arizona
Conditions: Cancer
Register for Updates
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study
NCT05053100
Recruiting
This study evaluates the risks and experience of blood clots and bleeding in patients with blood cancers. While it is standard of care to use medications to reduce the risk of blood clots in hospitalized individuals, some patients with blood cancers have low platelet counts that can increase the concern for bleeding complications associated with these medications. At this time, the optimal management strategies for blood clots are not well known for patients with blood cancers. This pilot study... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Acute Leukemia, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Thrombocytopenia
Register for Updates
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
NCT05094804
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Register for Updates
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03129139
Recruiting
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Register for Updates
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
NCT04042831
Recruiting
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Register for Updates
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT05002270
Recruiting
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: Mayo Clinc, Scottsdale, Arizona
Conditions: Advanced Solid Tumor, NSCLC, CRC
Register for Updates
Total Shoulder Arthroplasty Multi-Center Registry
NCT03511586
Recruiting
The objective of the study is a multi-center prospective registry to collect clinical outcomes of anatomic and reverse total shoulder arthroplasty.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/27/2023
Locations: Not set, Scottsdale, Arizona
Conditions: Shoulder Arthroplasty
Register for Updates
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
NCT04720976
Recruiting
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2023
Locations: Research Site, Scottsdale, Arizona
Conditions: Solid Tumor, NSCLC
Register for Updates
AVPI Migraine Study
NCT05537818
Recruiting
The study is designed as a multicenter, double-blind, randomized, sham-controlled trial to assess the safety and effectiveness of the Nocira AVPI Device for the acute treatment of migraine. The study is conducted in two phases in two study groups: Phase I - initial screening of device operation in both active and sham modes in-clinic and as proctored by the investigator, and Phase II - for further evaluation when used in the home (non-clinical) environment.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/08/2023
Locations: ReGen Pain & Wellness, Scottsdale, Arizona
Conditions: Migraine
Register for Updates